Another PARP Inhibitor Active in BRCA-Mutant Prostate Cancer
A third of patients with previously treated BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) responded to the PARP inhibitor niraparib (Zejula), a prospective phase II study showed. The results showed that 26 of 76 patients with measurable disease had objective responses, 35 of whom had at least a 30% decrease in tumor size. An exploratory analysis […]
Fewer Hepatitis C Patients Seeking Treatment of Late
The number of people with hepatitis C virus (HCV) treated with direct-acting antiviral agents (DAAs) dropped sharply in 2020, accelerating a decline that began in 2015, CDC researchers found. While 843,362 individuals from 2014-2020 were estimated to receive DAAs for HCV, only 83,740 initiated DAA treatment in 2020, down from 114,893 in 2019 and a […]
Words Matter to People Who Are Overweight
How a physician refers to a patient can influence how they are treated and how they feel about themselves and their doctors, which is why The Obesity Society (TOS) and four other organizations chose to kick off the annual ObesityWeek meeting with a policy statement promoting the idea that people come first, not diseases. “People-first […]
What Are the Long-Term Side Effects of Rheumatic Fever? Complications
If not promptly treated, rheumatic fever can have long-term side effects such as rheumatic heart disease, which weakens the valves between the heart’s chambers. The majority of rheumatic fever (RF) symptoms go away after a few weeks or months, but recurrence and certain complications are common. Usually, heart and joint ailments are long-term consequences of […]
PD-1 Inhibitor Boosts Survival in Treated Esophageal Cancer
Overall survival (OS) in previously treated esophageal cancer improved significantly with the anti-PD-1 drug tislelizumab compared to chemotherapy, a phase III, randomized trial showed. Patients randomized to tislelizumab had a median OS of 8.6 months as compared with 6.3 months for patients who received chemotherapy alone. A prespecified subgroup analysis of patients from Europe and […]